Physician profile
Brian Levine
NPI 1578541389
$4,731.06
in general payments reported to CMS, 2019-2025
19 companies · $14.34 in 2025
The $14.34 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $556 · 2021: $902 · 2022: $132 · 2023: $1,092 · 2024: $166 · 2025: $14.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,000 · Food and Beverage: $166 · Consulting Fee: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,000.00 |
| Food and Beverage | $165.63 |
| Consulting Fee | $106.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $1,106.00 | 2023-2024 | C-Mac |
| Novo Nordisk INC | $735.11 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $603.69 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.31 | 2021 | |
| Allergan, INC. | $365.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $355.34 | 2019-2021 | |
| Vifor Pharma, INC. | $214.57 | 2019 | |
| Ucb, INC. | $129.67 | 2020 | |
| Paratek Pharmaceuticals, INC. | $124.10 | 2021 | |
| Nabriva Therapeutics, Plc | $99.11 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $91.69 | 2023 | Inpefa |
| Acelrx Pharmaceuticals, INC. | $76.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $76.00 | 2022 | |
| Merck Sharp & Dohme LLC | $64.48 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $62.83 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $59.60 | 2024 | Xarelto |
| Terumo Medical Corporation | $55.80 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.94 | 2019-2020 | |
| Integra Lifesciences Corporation | $14.34 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.